<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01451411</url>
  </required_header>
  <id_info>
    <org_study_id>087-CL-096</org_study_id>
    <nct_id>NCT01451411</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol®) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia</brief_title>
  <official_title>A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center, Dose-Titration Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol®) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cumberland Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cumberland Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy, safety and pharmacokinetics of
      intravenous conivaptan in pediatric subjects with abnormally low concentration of sodium in
      blood.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A 3:1 randomization between conivaptan and placebo will be implemented and randomization will
      be further stratified in a 1:1:2 ratio for age groups: 2-5 years, 6-10 years, and 11-17
      years.

      Subjects will need to remain hospitalized for the 48-hour Treatment Period through Hour 96
      (Day 4). There will be a follow-up safety visit on Day 9 or day of hospital discharge,
      whichever occurs first. There is a final follow-up phone call at Day 32 to assess if any
      serious adverse events have occurred since hospital discharge.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Enrollment goals were not met.
  </why_stopped>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline to the End of the 48-hour Treatment Period in Serum Sodium</measure>
    <time_frame>baseline and 48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time From the First Dose of Study Medication to a Confirmed ≥ 4 mEq/L Increase From Baseline in Serum Sodium</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Confirmed ≥ 4 mEq/L Increase From Baseline in Serum Sodium</measure>
    <time_frame>baseline and 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Confirmed &gt; 6 mEq/L Increase From Baseline in Serum Sodium or a Confirmed Normal Serum Sodium Level (Greater Than or Equal to 135 mEq/L)</measure>
    <time_frame>baseline and 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Effective Water Clearance (EWC) Every 12 Hours</measure>
    <time_frame>Baseline, Hours 12, 24, 36 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Free Water Clearance (FWC)</measure>
    <time_frame>Baseline and 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an Overly Rapid Rise in Serum Sodium From Baseline</measure>
    <time_frame>baseline and Hours 3, 8, 12 and 24.</time_frame>
    <description>an absolute serum sodium of 145 mEq/L at Hour 24 or an increase in serum sodium of greater than 12 mEq/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population Pharmacokinetics: Clearance (CL)</measure>
    <time_frame>Up to Hour 60</time_frame>
    <description>Based on conivaptan concentrations, the pharmacokinetics of the study population will be analyzed to determine median CL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population Pharmacokinetics: Volume of Distribution (Vd)</measure>
    <time_frame>Up to Hour 60</time_frame>
    <description>Based on conivaptan concentrations, the pharmacokinetics of the study population will be analyzed to determine median Vd</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Hyponatremia</condition>
  <arm_group>
    <arm_group_label>Conivaptan hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conivaptan hydrochloride</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>Conivaptan hydrochloride</arm_group_label>
    <other_name>Vaprisol®</other_name>
    <other_name>YM087</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is euvolemic or hypervolemic hyponatremia upon clinical presentation

          -  Subject has serum sodium value ≥ 115 mEq/L (115 mmol/L) and &lt; 130 mEq/L (130 mmol/L)
             during the 24 hours preceding inclusion into the study

          -  Female subject of childbearing potential must have a negative serum pregnancy test and
             must be premenarchal, surgically sterile or must practice a method of birth control

        Exclusion Criteria:

          -  Female subject is pregnant or lactating

          -  Subject has a body mass index (BMI) &lt; the 3rd percentile or &gt; the 97th percentile for
             their age and stature according to the World Health Organization; Body mass
             index-for-age percentiles charts for boys and girls ages 2 to 20

          -  Subject has clinical evidence of volume depletion, dehydration or hypovolemia

          -  Subject with hypovolemic hyponatremia or transient causes of hyponatremia that are
             likely to resolve during the time of study participation

          -  Subjects with a cause of hyponatremia that is most appropriately corrected by
             alternative therapies

          -  Subject is expected to receive emergent treatment for hyponatremia during the
             treatment period of the study

          -  Subject has clinical evidence of hypotension

          -  Subject has uncontrolled hypertension &gt; the 99th percentile for their age

          -  Subject has uncontrolled bradyarrhythmias or tachyarrhythmias requiring emergent
             pacemaker placement or treatment

          -  Subject has untreated severe hypothyroidism, hyperthyroidism or adrenal insufficiency

          -  Subject has known urinary outflow obstruction, unless subject is, or can be
             catheterized during the study

          -  Subject has estimated creatinine clearance &lt; 30 mL/min during the seven days prior to
             study drug administration

          -  Subject has alanine aminotransferase (ALT) or aspartate aminotransferase (AST)
             elevations &gt; 3 times the upper limit of normal reference range during the seven days
             prior to study drug administration

          -  Subject has serum albumin ≤ 1.5 g/dL during the seven days prior to study drug
             administration

          -  Subject has white blood cell count (WBC) &lt; 3000/micro-liter documented any time during
             seven days prior to study drug administration or anticipated drop in WBC to &lt;
             3000/micro-liter during the period of the study due to chemotherapy

          -  Subject currently has unstable hepatic function or a history of hepatic
             encephalopathy, or bleeding esophageal varices within the last 3 months

          -  Subject has acute heart failure. Prior history of heart failure is allowed if there
             are no current signs/symptoms

          -  Subject has a non-fasting blood glucose value ≥ 275 mg/dL

          -  Subject requires or is suspected to require treatment with potent inhibitors or potent
             inducers of CYP3A4

          -  Subject was administered hypertonic saline or oral salt supplement within 24 hours
             prior to study drug administration

          -  Subject requires the use of medications used in the treatment of Syndrome of
             Inappropriate Antidiuretic Hormone Secretion (SIADH): including lithium salts, urea or
             demeclocycline during the week prior to screening and throughout the study drug
             treatment period

          -  Subject has any condition that may interfere with treatment or evaluation of safety

          -  Subject has received investigational therapy (including placebo) within 28 days or 5
             half lives, whichever is longer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Art Wheeler, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cumberland Pharmaceuticals Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of New York - Presbyterian</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Cardioinfantil - Instituto Cardiológico</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Valle del Lili</name>
      <address>
        <city>Cali, Valle</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Philippines</country>
  </removed_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2011</study_first_submitted>
  <study_first_submitted_qc>October 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2011</study_first_posted>
  <results_first_submitted>December 18, 2015</results_first_submitted>
  <results_first_submitted_qc>February 1, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 1, 2016</results_first_posted>
  <last_update_submitted>February 1, 2016</last_update_submitted>
  <last_update_submitted_qc>February 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Serum Sodium</keyword>
  <keyword>Euvolemia</keyword>
  <keyword>Hypervolemia</keyword>
  <keyword>Vaprisol®</keyword>
  <keyword>Conivaptan</keyword>
  <keyword>YM087</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyponatremia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conivaptan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Conivaptan Hydrochloride</title>
          <description>Conivaptan hydrochloride: Intravenous</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: Intravenous</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Conivaptan Hydrochloride</title>
          <description>Conivaptan hydrochloride: Intravenous</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: Intravenous</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>2 - 5 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 - 10 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 - 17 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline to the End of the 48-hour Treatment Period in Serum Sodium</title>
        <time_frame>baseline and 48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conivaptan Hydrochloride</title>
            <description>Conivaptan hydrochloride: Intravenous</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Intravenous</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to the End of the 48-hour Treatment Period in Serum Sodium</title>
          <units>mEq/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="5.3"/>
                    <measurement group_id="O2" value="-4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From the First Dose of Study Medication to a Confirmed ≥ 4 mEq/L Increase From Baseline in Serum Sodium</title>
        <time_frame>48 hours</time_frame>
        <population>Data from two subjects (one conivaptan, and one placebo) were censored as the serum sodium never achieved a value greater or equal to 4 mEq/L above the baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Conivaptan Hydrochloride</title>
            <description>Conivaptan hydrochloride: Intravenous</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Intravenous</description>
          </group>
        </group_list>
        <measure>
          <title>Time From the First Dose of Study Medication to a Confirmed ≥ 4 mEq/L Increase From Baseline in Serum Sodium</title>
          <population>Data from two subjects (one conivaptan, and one placebo) were censored as the serum sodium never achieved a value greater or equal to 4 mEq/L above the baseline value.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5" lower_limit="2.5" upper_limit="40.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Confirmed ≥ 4 mEq/L Increase From Baseline in Serum Sodium</title>
        <time_frame>baseline and 48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conivaptan Hydrochloride</title>
            <description>Conivaptan hydrochloride: Intravenous</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Intravenous</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Confirmed ≥ 4 mEq/L Increase From Baseline in Serum Sodium</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Confirmed &gt; 6 mEq/L Increase From Baseline in Serum Sodium or a Confirmed Normal Serum Sodium Level (Greater Than or Equal to 135 mEq/L)</title>
        <time_frame>baseline and 48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conivaptan Hydrochloride</title>
            <description>Conivaptan hydrochloride: Intravenous</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Intravenous</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Confirmed &gt; 6 mEq/L Increase From Baseline in Serum Sodium or a Confirmed Normal Serum Sodium Level (Greater Than or Equal to 135 mEq/L)</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Effective Water Clearance (EWC) Every 12 Hours</title>
        <time_frame>Baseline, Hours 12, 24, 36 and 48</time_frame>
        <population>The protocol specifies that calculations for this endpoint were to be derived by the statistical team. Due to the terminated status of the study, a statistical team was not employed and calculations to determine this variable were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Conivaptan Hydrochloride</title>
            <description>Conivaptan hydrochloride: Intravenous</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Intravenous</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Effective Water Clearance (EWC) Every 12 Hours</title>
          <population>The protocol specifies that calculations for this endpoint were to be derived by the statistical team. Due to the terminated status of the study, a statistical team was not employed and calculations to determine this variable were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Free Water Clearance (FWC)</title>
        <time_frame>Baseline and 48 hours</time_frame>
        <population>The protocol specifies that calculations for this endpoint were to be derived by the statistical team. Due to the terminated status of the study, a statistical team was not employed and calculations to determine this variable were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Conivaptan Hydrochloride</title>
            <description>Conivaptan hydrochloride: Intravenous</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Intravenous</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Free Water Clearance (FWC)</title>
          <population>The protocol specifies that calculations for this endpoint were to be derived by the statistical team. Due to the terminated status of the study, a statistical team was not employed and calculations to determine this variable were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an Overly Rapid Rise in Serum Sodium From Baseline</title>
        <description>an absolute serum sodium of 145 mEq/L at Hour 24 or an increase in serum sodium of greater than 12 mEq/L</description>
        <time_frame>baseline and Hours 3, 8, 12 and 24.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conivaptan Hydrochloride</title>
            <description>Conivaptan hydrochloride: Intravenous</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Intravenous</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Overly Rapid Rise in Serum Sodium From Baseline</title>
          <description>an absolute serum sodium of 145 mEq/L at Hour 24 or an increase in serum sodium of greater than 12 mEq/L</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Population Pharmacokinetics: Clearance (CL)</title>
        <description>Based on conivaptan concentrations, the pharmacokinetics of the study population will be analyzed to determine median CL</description>
        <time_frame>Up to Hour 60</time_frame>
        <population>Due to the terminated status of the study, pharmacokinetic samples were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Conivaptan Hydrochloride</title>
            <description>Conivaptan hydrochloride: Intravenous</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Intravenous</description>
          </group>
        </group_list>
        <measure>
          <title>Population Pharmacokinetics: Clearance (CL)</title>
          <description>Based on conivaptan concentrations, the pharmacokinetics of the study population will be analyzed to determine median CL</description>
          <population>Due to the terminated status of the study, pharmacokinetic samples were not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Population Pharmacokinetics: Volume of Distribution (Vd)</title>
        <description>Based on conivaptan concentrations, the pharmacokinetics of the study population will be analyzed to determine median Vd</description>
        <time_frame>Up to Hour 60</time_frame>
        <population>Due to the terminated status of the study, pharmacokinetic samples were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Conivaptan Hydrochloride</title>
            <description>Conivaptan hydrochloride: Intravenous</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Intravenous</description>
          </group>
        </group_list>
        <measure>
          <title>Population Pharmacokinetics: Volume of Distribution (Vd)</title>
          <description>Based on conivaptan concentrations, the pharmacokinetics of the study population will be analyzed to determine median Vd</description>
          <population>Due to the terminated status of the study, pharmacokinetic samples were not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through Day 32</time_frame>
      <desc>Serious adverse events were collected through Day 32; non-serious adverse events were collected through Day 9.</desc>
      <group_list>
        <group group_id="E1">
          <title>Conivaptan Hydrochloride</title>
          <description>Conivaptan hydrochloride: Intravenous</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: Intravenous</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Stevens_Johnson Syndrome</sub_title>
                <description>Onset of SAE was on Day 32 following initiation of investigational drug. The event was deemed as not related by the Investigator.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Accelerated idioventricular rhythm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI can publish data generated at their study site after multi-center study data have already been published, or after 18 months have elapsed following database lock, whichever comes first. The sponsor may review manuscripts before submission and delay publication by an additional 60 days, if necessary.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Amy Rock, PhD</name_or_title>
      <organization>Cumberland Pharmaceuticals Inc.</organization>
      <phone>615-255-0068</phone>
      <email>arock@cumberlandpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

